Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The future direction and unmet needs of transplant immunosuppression.Expert Rev Clin Pharmacol. 2016; 9: 873-876
- Long-term renal allograft survival in the United States: a critical reappraisal.Am J Transplant. 2011; 11: 450-462
- Through a glass darkly: seeking clarity in preventing late kidney transplant failure.J Am Soc Nephrol. 2015; 26: 20-29
- Current and future immunosuppressive therapies: impact on chronic allograft dysfunction.J Nephrol. 1997; 10: 229-231
- ISA(TX)247: a novel calcineurin inhibitor.Transpl Proc. 2001; 33: 1048-1051
- The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.Am J Transplant. 2011; 11: 2675-2684
- Tofacitinib in kidney transplantation.Expert Opin Investig Drugs. 2013; 22: 1193-1199
- Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients.Am J Transplant. 2009; 9: 1936-1945
- Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.Am J Transplant. 2012; 12: 2446-2456
- Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.Am J Transplant. 2015; 15: 1644-1653
- Tofacitinib in renal allograft recipients: long-term efficacy and safety in an active-comparator-controlled extension trial.Transplantation. 2016; 100: S84-S85
- The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.J Pharmacol Exp Ther. 2009; 330: 792-801
- Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.Transpl Int. 2010; 23: 543-552
- Sotrastaurin (AEB071) alone and in combination with cyclosporine A prolongs survival times of non-human primate recipients of life-supporting kidney allografts.Transplantation. 2012; 93: 156-164
- Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients.Am J Transplant. 2013; 13: 1757-1768
- Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.Am J Transplant. 2013; 13: 1746-1756
- CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism.Nat Med. 2002; 8: 247-252
- Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects.Am J Transplant. 2014; 14: 1290-1299
- Clinical outcomes in a Phase 1b, randomized, double blinded, parallel group, placebocontrolled, single dose study of ASKP1240 in de novo kidney transplantation.Am J Transplant. 2013; 13: 86
- ASKP1240 in de novo kidney transplant recipients.Am J Transplant. 2015; 15
- 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses.J Exp Med. 2014; 211: 297-311
- Costimulation blockade in autoimmunity and transplantation: the CD28 pathway.J Immunol. 2016; 197: 2045-2050
- FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft.Am J Transplant. 2015; 15: 88-100
- HLA-mismatched renal transplantation without maintenance immunosuppression.N Engl J Med. 2008; 358: 353-361
- Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients.Transplant Proc. 2009; 41: 3655-3661
- The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human alphabeta T cell receptor antibody, in renal transplant patients.Clin Pharmacokinet. 2014; 53: 649-657
- First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection.Am J Transplant. 2014; 14: 1346-1355
- A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.Am J Transplant. 2007; 7: 1770-1777
- Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial.Am J Transplant. 2013; 13: 1724-1733
- One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial.Transplantation. 2016; 100: 391-399
- Current status of antibody therapy in ALL.Br J Haematol. 2015; 168: 471-480
- Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.Clin Cancer Res. 2015; 21: 1267-1272
- First case report of using Ofatumumab in kidney transplantation AB0 incompatible.G Ital Nefrol. 2017; 34 ([pii:2017-vol6])
- BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses.Eur J Immunol. 2004; 34: 2750-2759
- Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF.Transplantation. 2012; 93: 676-685
- BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies.Am J Transplant. 2012; 12: 2754-2762
- Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection.Transplantation. 2013; 96: 413-420
- Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.Lancet. 2018; 391: 2619-2630
- Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.Arthritis Res Ther. 2006; 8: R74
- Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS--a novel therapeutic opportunity.PLoS One. 2015; 10: e0132011
- The bacterial enzyme IdeS cleaves the IgG-type of B cell receptor (BCR), abolishes BCR-mediated cell signaling, and inhibits memory B cell activation.J Immunol. 2015; 195: 5592-5601
- IdeS (Imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody.Ann Surg. 2018; 268: 488-496
- Belatacept and long-term outcomes in kidney transplantation.N Engl J Med. 2016; 374: 333-343
- Follicular T helper cells and humoral reactivity in kidney transplant patients.Clin Exp Immunol. 2015; 180: 329-340
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.Blood. 2012; 120: 5185-5187
- Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than Lutetium-177 for treatment of multiple myeloma in a preclinical model.Front Med (Lausanne). 2015; 2: 76
- A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (Tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients.Transplantation. 2015; 99: 2356-2363
- Eosinophils are required for the maintenance of plasma cells in the bone marrow.Nat Immunol. 2011; 12: 151-159
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.Lancet. 2012; 380: 651-659
- Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.Curr Opin Allergy Clin Immunol. 2016; 16: 186-200
- Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.Am J Transplant. 2015; 15: 815-822
- Effect of treatment with tabalumab, a B Cell-activating factor inhibitor, on highly sensitized patients with end-stage renal disease awaiting transplantation.Am J Transplant. 2016; 16: 1266-1275
- The role of complement in antibody-mediated rejection in kidney transplantation.Nat Rev Nephrol. 2012; 8: 670-678
- The harmful role of c5a on innate immunity in sepsis.J Innate Immun. 2011; 2: 439-445
- Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.Am J Transplant. 2011; 11: 2405-2413
- Antibody-mediated rejection despite inhibition of terminal complement.Transpl Int. 2014; 27: 1235-1243
- Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.Am J Transplant. 2018; 18: 916-926
- C1 inhibitor, a multi-functional serine protease inhibitor.Thromb Haemost. 2010; 104: 886-893
- Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study.Am J Transplant. 2016; 16: 3468-3478
Behring C. Efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory Antibody Mediated Rejection (AMR) in adult renal transplant recipients (NCT03221842). 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT03221842.
Shire. A multicenter study to evaluate the efficacy and safety of Cinryze® for the treatment of acute antibody-mediated rejection in participants with kidney transplant(ClinicalTrials.gov Identifier: NCT02547220). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02547220.
Article info
Publication history
Published online: December 17, 2018
Footnotes
Disclosure Statement: The authors have nothing to disclose.
I. Grgic was supported by the Deutsche Forschungsgemeinschaft and grants from the Philipps-University Marburg, University Medical Center Giessen and Marburg, and the Von Behring-Roentgen- Foundation.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
